新药时代自体造血干细胞移植治疗多发性骨髓瘤的地位

[1]	Cavo M,Rajkumar SV,Palumbo A,et al.International Myeloma Working Group.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation[J].Blood,2011,117:6063-6073.
[2]	Moreau P,Avet-Loiseau H,Harousseau JL,et al.Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies[J].J Clin Oncol,2011,29:1898-1906.
[3]	Palumbo A,Rajkumar SV,San Miguel JF,et al.International Myeloma Working Group consensus statement for the management,treatment,and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J].J Clin Oncol,2014,32:587-600.
[4]	Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase III trial[J].J Clin Oncol,2010,28:4621-4629.
[5]	Cavo M,Tacchetti P,Patriarca F,et al.GIMEMA Italian Myeloma Network.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before,and consolidation therapy after,double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomized phase 3 study[J].Lancet,2010,376:2075-2085.
[6]	Moreau P,Avet-Loiseau H,Facon T,et al.Bortezomib plus dexamethasone versus reduced-dose bortezomib,thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma[J].Blood,2011,118:5752-5758,quiz 5982.
[7]	Rosiñol L,Oriol A,Teruel AI,et al.Superiority of bortezomib,thalidomide,and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J].Blood,2012,120:1589-1596.
[8]	Moreau P,Facon T,Attal M,et al.Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial[J].Blood,2002,99:731-735.
[9]	Bayraktar UD,Bashir Q,Qazilbash M,et al.Fifty years of melphalan use in hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19:344-356.
[10]	Roussel M,Moreau P,Huynh A,et al.Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma:a phase 2 study of the Intergroupe Francophone du Myelome (IFM)[J].Blood,2010,115:32-37.
[11]	Cavo M,Tosi P,Zamagni E,et al.Prospective,randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma:Bologna 96 clinical study[J].J Clin Oncol,2007,25:2434-2441.
[12]	Attal M,Harousseau JL,Facon T,et al.Single versus double autologous stem-cell transplantation for multiple myeloma[J].N Engl J Med,2003,349:2495-2502.[JP]
[13]	Sonneveld P,Schmidt-Wolf IG,van der Holt B,et al.Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase III HOVON-65/GMMG-HD4 trial[J].J Clin Oncol,2012,30:2946-2955.
[14]	Cavo M,Pantani L,Petrucci MT,et al.Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma[J].Blood,2012,120:9-19.
[15]	Mellqvist UH,Gimsing P,Hjertner O,et al.Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma:a Nordic Myeloma Study Group randomized phase 3 trial[J].Blood,2013,121:4647-4654.
[16]	Leleu X,Fouquet G,Hebraud B,et al.Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma[J].Leukemia,2013,27:2242-2244.
[17]	Barlogie B,Pineda-Roman M,van Rhee F,et al.Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J].Blood,2008,112:3115-3121.
[18]	Attal M,Harousseau JL,Leyvraz S,et al.Maintenance therapy with thalidomide improves survival in multiple myeloma patients[J].Blood,2006,108:3289-3294.
[19]	Morgan GJ,Gregory WM,Davies FE,et al.The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J].Blood,2012,119:7-15.
[20]	Attal M,Lauwers-Cances V,Marit G,et al.Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J].N Engl J Med,2012,366:1782-1791.
[21]	McCarthy PL,Owzar K,Hofmeister CC,et al.Lenalidomide after stem-cell transplantation for multiple myeloma[J].N Engl J Med,2012,366:1770-1781.
[22]	Palumbo A,Bringhen S,Kumar SK,et al.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma:a meta-analysis of individual patient data[J].Lancet Oncol,2014,15:333-342.
[23]	Rajkumar SV,Jacobus S,Callander NS,et al.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomised controlled trial[J].Lancet Oncol,2010,11:29-37.
[24]	Kumar SK,Lacy MQ,Dispenzieri A,et al.Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J].Cancer,2012,118:1585-1592.
[25]	Dunavin NC,Wei L,Elder P,et al.Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma[J].Leuk Lymphoma,2013,54:1658-1664.
[26]	Palumbo A,Cavallo F,Gay F,et al.Autologous transplantation and maintenance therapy in multiple myeloma[J].N Engl J Med,2014,371:895-905.
[27]	Siegel DS,Jacobus S,Rajkumar SV,et al.Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial[abstract].Blood,2010,116:Abstract 38.
[28]	Palumbo A,Gay F,Spencer A,et al.A phase III study of ASCT vs cyclophosphamidelenalidomide-dexamethasone and lenalidomideprednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients[abstract].Blood,2013,122:Abstract 763.